Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 4/20 | 0.39 |
| ▸ | HRH1 | P35367 | 4/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7255639 | 0.84 | TAAR1 (0.45) | TAAR1 | |
| SCHEMBL7259968 | 0.84 | TAAR1 (0.45) | TAAR1 | |
| SCHEMBL7255641 | 0.84 | TAAR1 (0.45) | TAAR1 | |
| SCHEMBL27984691 | 0.82 | CA12 (0.36) | CA12CA1CA2CA9CA7 | |
| SCHEMBL5159743 | 0.82 | LMNA (0.48) | CYP1A2CYP2D6 | |
| SCHEMBL2542325 | 0.82 | LMNA (0.48) | CYP1A2CYP2D6 | |
| SCHEMBL11041406 | 0.82 | MMP13 (0.38) | CA12CA1CA2CA9CA7 | |
| SCHEMBL2541606 | 0.82 | LMNA (0.48) | CYP1A2CYP2D6 | |
| SCHEMBL11044378 | 0.82 | CA1 (0.36) | CA12CA1CA2CA9CA7 | |
| SCHEMBL11043161 | 0.82 | TSHR (0.37) | CA12CA1CA2CA9CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103649075-B | Isosorbide-5-Nitrae-dihydropyridine-3,5-dicarboxylate derivatives and preparation and application thereof | XUANZHU PHARMA CO.,LTD. (CN) | 2016-05-25 | — | — | CN | disclosed |
| US-9198902-B2 | 1,4-dihydropyridine-3,5-dicarboxylate derivatives and preparation and use thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2015-12-01 | — | — | US | disclosed |
| US-9198902-B2 | 1,4-dihydropyridine-3,5-dicarboxylate derivatives and preparation and use thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2015-12-01 | — | — | US | disclosed |
| US-9198902-B2 | 1,4-dihydropyridine-3,5-dicarboxylate derivatives and preparation and use thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2015-12-01 | — | — | US | disclosed |
| CN-103649075-A | 1,4-dihydropyridine-3,5-dicarboxylate derivatives, preparation methods and uses thereof | KBP BIOSCIENCES CO LTD | 2014-03-19 | — | — | CN | disclosed |
| EP-2703398-A1 | 1,4-DIHYDROPYRIDINE -3,5-DICARBOXYLATE DERIVATIVES, PREPARATION METHODS AND USES THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2014-03-05 | — | — | EP | disclosed |
| EP-2703398-A1 | 1,4-DIHYDROPYRIDINE -3,5-DICARBOXYLATE DERIVATIVES, PREPARATION METHODS AND USES THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2014-03-05 | — | — | EP | disclosed |
| US-20140045896-A1 | 1,4-dihydropyridine-3,5-dicarboxylate Derivatives And Preparation And Use Thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2014-02-13 | — | — | US | disclosed |
| US-20140045896-A1 | 1,4-dihydropyridine-3,5-dicarboxylate Derivatives And Preparation And Use Thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2014-02-13 | — | — | US | disclosed |
| US-20140045896-A1 | 1,4-dihydropyridine-3,5-dicarboxylate Derivatives And Preparation And Use Thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2014-02-13 | — | — | US | disclosed |
| US-6417213-B2 | ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-07-09 | — | — | US | disclosed |
| US-20020006944-A1 | Tricyclic compounds, their production and use | OHKAWA SHIGENORI (JP) | 2002-01-17 | — | — | US | disclosed |
| US-6248766-B1 | CARDIOVASCULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
| EP-0929534-A1 | TRYCYCLIC COMPOUNDS AS PROSTAGLANDIN I2 RECEPTOR AGONISTS | Takeda Pharmaceutical Company Limited (JP) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998013356-A1 | TRYCYCLIC COMPOUNDS AS PROSTAGLANDIN I2 RECEPTOR AGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006944-A1 | Tricyclic compounds, their production and use | CNR1, PTGER1, PTGDR | CA12 3731/4885CA1 2224/4885CA2 770/4885 |
| US-20140045896-A1 | 1,4-dihydropyridine-3,5-dicarboxylate Derivatives And Preparation And Use Thereof | PKD1, REN, GLS | CA12 2775/4885CA1 1135/4885CA2 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.